×
About 264,784 results

Now Approved: TRODELVY™ - Sacituzumab Govitecan-hziy‎
https://www.trodelvy.com

Official Site: Learn about TRODELVY™, Clinical Study Results. FDA approved. See Full Safety and Prescribing Information including boxed Warning. Prescribing Information. Safety. Dosing. Financial Support.

Now Approved Treatment - ONGENTYS® (opicapone)‎
https://www.ongentyshcp.com

HCPs: Learn about a now-approved treatment option for your patients. Discover ONGENTYS. Sign up to receive updates about ONGENTYS. View Press Release. Contact a Rep. See Full PI. Now Approved. See Full PI. View Press Release. Sign Up for Updates.

KOSELUGO™ (selumetinib) - Official Website‎
https://www.koselugo.com

Learn More Information About Now FDA-Approved KOSELUGO On The Official Site. Resources Available. Important Safety Info. Indication Info. Download Prescribing Info. Access 360 Program. Insurance coverage: Financial Support Info, Access 360 Program.

JELMYTO - Official HCP Website - See Prescribing Information‎
https://www.jelmyto.com/hcp

Read More Information About JELMYTO™ (mitomycin) for pyelocalyceal solution. Dosing Information. Healthcare Professionals. Key Clinical Data.

PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp]
https://www.palforziapro.com

PALFORZIA is the first and only FDA-approved oral immunotherapy for peanut allergy in patients aged 4 through 17 years.

Prescription Drug Pricing Transparency Law Comparison Chart
https://www.nashp.org/prescription-drug-pricing-transparency-law-comparison-chart/
The National Academy for State Health Policy (NAHSP)

A number of states have enacted drug pricing transparency laws requiring drug supply chain entities such as manufacturers, pharmacy benefit managers, health plans, and others to report information explaining high price increases and high-priced new drugs. This chart compares states’ transparency laws, each tab provides an overview of required reporting from specific supply chain entities. To le...

Drugs@FDA: FDA-Approved Drugs
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=report.page
US Food and Drug Administration (FDA)

This report displays final approvals and tentative approvals of original and supplemental applications for the two weeks beginning on the earliest date listed below. Some approvals may be added to the Drugs@FDA database after this timespan. For comprehensive approval reports, please use the monthly "All Approvals" report on Drugs@FDA.

Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients
https://clinicaltrials.gov/ct2/show/NCT04718480

Jan 21st, 2021 - This is a randomized, double-blind, placebo-controlled, adaptive two-stage design, human phase 2 study, with add-on treatment arrangement of fluvoxamine or placebo on top of standard of care (base therapy: the actual proposed therapy of moderate SARS-CoV-2 infected patients according to "Hungarian Coronavirus Handbook", including antiviral and immunmodulant therapy and reconvalescent plasma the...

Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19
https://investor.lilly.com/news-releases/news-release-details/lillys-bamlanivimab-and-etesevimab-together-reduced
Eli Lilly and Company

Mar 9th, 2021 - INDIANAPOLIS, March 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 3 study, demonstrating bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together significantly reduced COVID-19 related hospitalizations and deaths ("events") in high-risk patients recently diagnosed with CO...

FDA approves niraparib for first-line maintenance of advanced ovarian cancer
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer
FDA

Apr 28th, 2020 - The Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.

FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-capmatinib-metastatic-non-small-cell-lung-cancer
FDA

May 5th, 2020 - On May 6, 2020, the Food and Drug Administration granted accelerated approval to capmatinib (TABRECTA, Novartis) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

Retevmo™ (selpercatinib)‎ - Visit The Official Site‎
https://www.retevmo.com/

View Safety & Prescribing Information On The Official Patient Site. Learn How Retevmo™ Works And How It May Help Eligible Patients. Savings & Support. Dosing and Administration. About RETEVMO™. Types: Patient Resources, Treatment Information, Safety Information.

DARZALEX Faspro™ - Info for Physicians‎
https://www.darzalexhcp.com

(daratumumab and hyaluronidase human-fihj) Learn More at the Official Physician Site. Prescription Assistance. Patient Support Program. Dosing Admin & Safety. Janssen CarePath. Official Physician Site. Learn About Multiple MOAs. Patient Dosing Schedule.

TABRECTA™ (capmatinib) - Now Approved - HCP Site‎
https://www.hcp.novartis.com/products/tabrecta/met-exon-14-skipping-mutation-nsclc/efficacy/?site=MTX-1228793GK104516&source=01030&gclid=EAIaIQobChMIqfz855_K6QIVCZezCh1p0gOqEAAYAiAAEgJWYPD_BwE&gclsrc=aw.ds

HCPs, Visit The Official Site For Information About TABRECTA™ As A Treatment Option. See If TABRECTA™ Could Be Right For Your Patients. Full Safety Profile. Patient Co-Pay Program. Mechanism Of Action. Newly FDA Approved. Official HCP Website. Clinical Trial Data.

ACT® DRY MOUTH PRODUCTS
http://www.actoralcare.com/dental-professionals/act-dry-mouth/

ACT® Dry Mouth | ACT® Anticavity Fluoride Rinse

ACT® ADVANCED CARE™ PLAQUE GUARD™
http://www.actoralcare.com/dental-professionals/new-act-advanced-care-plaque-guard/

ACT® Advanced Care™ Plaque Guard™ | ACT® Anticavity Fluoride Rinse

A First-line Oral Treatment for Certain People with Gaucher Disease Type 1
http://www.cerdelga.com/healthcare-professionals.html

CERDELGA is a glucosylceramide synthase inhibitor indicated for the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.

ACT® FLUORIDE MOUTHWASH
http://www.actoralcare.com/dental-professionals/act-adult-fluoride-mouthwash/

ACT® Adult Fluoride Mouthwash | ACT® Anticavity Fluoride Rinse

ADEMPAS (riociguat) tablets
http://adempas-us.com/hcp/

Adempas (riociguat). Visit Adempas-US.com to see full safety and prescribing information, including Boxed Warning. Learn about Adempas and the Aim Patient Support Program.

ACNIZIL™ topical gel
https://www.henryschein.com/us-en/Medical/ShopExp/Acnizil.aspx

Acnizil™ is a new first-line therapy product for mild to severe acne. It is made from a proprietary silver solution